Extensive research corroborates that DGAT1 exacerbates lipid storage in hepatocytes (de la Rosa Rodriguez et al., 2021), and drugs targeting this protein can reduce liver fibrosis and inflammation in a murine NASH model (Cheng et al., 2022). This evidence concerns the gene DGAT1 and metabolic dysfunction-associated steatohepatitis.